- SpectronRx has entered a commercial supply agreement with Cellectar Biosciences to manufacture iopofosine I 131, a promising cancer therapy.
- The drug, currently in clinical trials for multiple cancers, will be produced at SpectronRx’s facilities in Indiana and Belgium.
SpectronRx has signed a commercial supply agreement with Cellectar Biosciences, Inc. to manufacture iopofosine I 131, a promising first-in-class cancer therapy. This agreement marks a significant step in the development and global distribution of the drug, which has shown efficacy in treating Waldenstrom’s macroglobulinemia (WM) and other cancers.
Under the agreement, SpectronRx, a contract developer and manufacturer of radiopharmaceuticals, will leverage its advanced facilities in Indiana and Belgium to produce iopofosine I 131. The drug has demonstrated impressive efficacy in the CLOVER-WaM pivotal study, surpassing both primary and secondary endpoints for patients with relapsed or refractory WM.
The therapy is also under investigation in Phase 2 studies for multiple myeloma (MM) and central nervous system (CNS) lymphoma, with additional studies targeting pediatric patients with high-grade gliomas. Cellectar plans to submit a New Drug Application (NDA) for iopofosine I 131 in the near future.
James Caruso, CEO of Cellectar, highlighted the strategic importance of this partnership in strengthening the company’s global supply network. He noted that SpectronRx’s facilities offer significant logistical advantages, supporting Cellectar’s expansion into global markets.
John Zehner, CEO of SpectronRx, emphasized the alignment between the companies, stating, “Our partnership with Cellectar aligns with our commitment to support innovative radiopharmaceutical developers in delivering life-changing treatments globally.”
Read about the Radiopharmaceutical CDMO Market Here.
Overview of outsourcing trends 
